Blastomycosis

Summary

Blastomycosis (MONDO:0005672) is a disease and 8 clinical trials. Top therapeutic interventions include itraconazole, amphotericin b, and fluconazole. A subtype of primary systemic mycosis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 8

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	blastomycosis
Mondo ID	MONDO:0005672
EFO	EFO:0007174
MeSH	D001759
DOID	DOID:12663
ICD-10-CM	B40
ICD-11	1968108845
NCIT	C34428, C34429
SNOMED CT	191950004
UMLS	C0005716
MedGen	597
Is cancer (heuristic)	no

Also known as: Blastomyces dermatitidis caused disease or disorder · Blastomyces dermatitidis disease or disorder · Blastomyces dermatitidis infection · Blastomyces dermatitidis infectious disease · blastomycotic infection · infection by Blastomyces dermatitidis · North American blastomycosis

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › fungal infectious disease › systemic mycosis › primary systemic mycosis › blastomycosis

Related subtypes (5): adiaspiromycosis, allescheriosis, coccidioidomycosis, paracoccidioidomycosis, histoplasmosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

2 approved, 2 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Itraconazole	Approved (phase 4)
Ketoconazole	Approved (phase 4)
Amphotericin B	Phase 3 (in late-stage trials)
Ibrexafungerp	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Fluconazole.

Clinical trials & evidence

Clinical trials

Clinical trials: 8.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	3
Not specified	2
PHASE4	1
PHASE2	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02283905	PHASE4	TERMINATED	Amphotericin-B and Voriconazole for Pulmonary Blastomycosis
NCT00002159	PHASE3	COMPLETED	A Randomized, Open, Comparative Multicenter Study of Initial Treatment With Intravenous Itraconazole Versus Amphotericin B Followed by Consolidation Treatment With Itraconazole Capsules in Patients With Blastomycosis or Histoplasmosis
NCT00784368	PHASE3	COMPLETED	A Pharmacokinetic Study of JK1211(Itraconazole [Itrizole]) Oral Solution in Participants With Deep Mycosis and Those With Febrile Neutropenia Suspected of Fungal Infection
NCT03059992	PHASE3	COMPLETED	Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment
NCT00004808	PHASE2	COMPLETED	Phase II Pilot Study of Fluconazole for Histoplasmosis, Blastomycosis, and Sporotrichosis
NCT00004811	PHASE1/PHASE2	COMPLETED	Phase I/II Study of Itraconazole for Blastomycosis, Histoplasmosis, and Sporotrichosis
NCT00001702	Not specified	COMPLETED	Evaluation of the Association of Polymorphisms in the Innate Immune System With the Risk for Blastomycosis Dermatitidis Infection in Patients Not Infected With HIV and Complications Associated With Blastomycosis Dermatitidis Infection
NCT06523998	Not specified	COMPLETED	A Study on Rare Dermatological Infections Conducted at Three Major Reference Hospitals in Costa Rica.

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ITRACONAZOLE	4	3
AMPHOTERICIN B	4	2
FLUCONAZOLE	4	1
IBREXAFUNGERP	4	1
VORICONAZOLE	4	1
CHEMBL4764856	0	1
HYOSCYAMINE	-1	2